{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-260299","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.836026+00:00","generated_at":"2026-06-09T16:45:59.233657+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Revolution Medicines reports Phase 1/1b data for RMC-6236 in NSCLC and PDAC; plans Phase 3 in 2024","bullets":["RMC-6236 showed ORR 38% (DCR 85%) in evaluable NSCLC (n=40) and ORR 20% (DCR 87%) in PDAC (n=46) as of Oct 12, 2023.","Safety at ≥80 mg daily: mostly Grade 1-2 rash/GI events; one Grade 4 perforation led to discontinuation; no fatal TRAEs.","Company plans global randomized Phase 3 trial of RMC-6236 vs docetaxel in RAS-mutated NSCLC, aiming to start in 2024.","Potential Phase 3 vs physician's choice in PDAC and combo pivotal trials also planned, pending further data and regulatory feedback.","RMC-4630 combo with sotorasib showed additive toxicity without sufficient benefit; no further development for that combination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-260299","json":"https://secwatch.observer/filing/0001193125-23-260299.json","markdown":"https://secwatch.observer/filing/0001193125-23-260299.md","text":"https://secwatch.observer/filing/0001193125-23-260299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523260299/0001193125-23-260299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523260299/d567415d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T16:45:59.233657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}